|
gptkbp:instanceOf
|
gptkb:drug
antidote
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2018
|
|
gptkbp:ATCCode
|
V03AB38
|
|
gptkbp:brand
|
Andexxa
Ondexxya
|
|
gptkbp:CASNumber
|
1006822-07-2
|
|
gptkbp:chemicalFormula
|
C_1980H_3063N_555O_620S_21
|
|
gptkbp:developedBy
|
gptkb:Portola_Pharmaceuticals
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
andexanet alfa
|
|
gptkbp:indication
|
uncontrolled bleeding
life-threatening bleeding
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:protein
|
|
gptkbp:mechanismOfAction
|
acts as decoy receptor
binds factor Xa inhibitors
|
|
gptkbp:pregnancyCategory
|
not assigned (US)
|
|
gptkbp:product
|
modified human factor Xa
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:pneumonia
urinary tract infection
infusion-related reactions
thromboembolic events
|
|
gptkbp:target
|
gptkb:rivaroxaban
gptkb:apixaban
gptkb:edoxaban
gptkb:enoxaparin
|
|
gptkbp:UNII
|
Q2I0K7RF0N
|
|
gptkbp:usedFor
|
reversal of anticoagulation
reversal of factor Xa inhibitors
|
|
gptkbp:bfsParent
|
gptkb:rivaroxaban
|
|
gptkbp:bfsLayer
|
6
|